How a long-known biomarker backs BioNTech’s antibody for pancreatic cancer
September 12, 2019 The team found that blocking CA19-9 could serve as a therapeutic strategy to prevent the progression from chronic pancreatitis to pancreatic cancer. The findings were just published in the journal Science, but they have already been translated into an antibody drug acquired by BioNTech called MVT-5873. The CA19-9 antibody is already in … Read more